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Objective. To assess the value of C-reactive protein (CRP) in predicting postinfarct left ventricular remodelling (LVR). Methods.
We measured in-hospital plasma CRP concentrations in patients with a first ST-segment elevation myocardial infarction (STEMI).
Results. LVR was present at 6 months in 27.8% of 198 patients. CRP concentration rose during the first 24 h, mainly in LVR group.
The prevalence of LVR was higher in patients from the highest quartile of CRP concentrations at 24 h as compared to those
from any other quartile (odds ratio (OR) 3.48, 95% confidence interval (95% CI) 1.76–6.88). Multivariate analysis identified
CRP concentration at 24 h (OR for a 10 mg/L increase 1.29, 95% CI 1.04–1.60), B-type natriuretic peptide at discharge (OR for
a 100 pg/mL increase 1.21, 95% CI 1.05–1.39), body mass index (OR for a 1 kg/m2 increase 1.10, 95% CI 1.01–1.21), and left
ventricular end-diastolic volume (OR for a 1 mL increase 0.98, 95% CI 0.96-0.99) as independent predictors of LVR. The ROC
analysis revealed a limited discriminative value of CRP (area under the curve 0.61; 95% CI 0.54–0.68) in terms of LVR prediction.
Conclusions. Measurement of CRP concentration at 24 h after admission possesses a significant but modest value in predicting LVR
after a first STEMI.
1. Introduction
Left ventricular remodelling (LVR) often complicates acute
ST-segment elevation myocardial infarction (STEMI) [1, 2].
The acute loss of myocardium results in an abrupt increase
in loading conditions that induces LVR, the process by
which ventricular size, shape, and function are regulated by
mechanical, neurohormonal, and genetic factors [3]. Postin-
farct LVR leads to a progressive rise in systolic and diastolic
left ventricular volumes, distortion of ventricular shape and
mural hypertrophy, in the weeks and months after STEMI
[3]. It has been identified as an important marker of poor
prognosis, linked with excessive cardiovascular mortality
and risk of heart failure [1–4]. The major determinants
of LVR after STEMI include infarct size, anterior location
of infarction, and late or unsuccessful reperfusion therapy
both at the epicardial artery level and at the microvascular
level, transmurality of the infarct and extent of myocardial
stunning [3–7].
Acute myocardial infarction (MI) is associated with a
systemic inflammatory response with augmented production
of nonspecific plasma acute-phase proteins, including C-
reactive protein (CRP) [8]. The increase in plasma CRP
concentration in the course of acute MI takes place in the
first hours since the onset of symptoms and peaks approxi-
mately on day 2 [8]. The cytokines released in the progress of
myocardial damage influence reactions affecting the expan-
sion of necrosis and scar formation such as cell growth and
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migration as well as repairing processes [9, 10]. The tissue
inflammatory response is not limited to the area of necrosis,
but it extends to the intact portions of myocardium, where
the expression of inflammatory cytokines continues to be
modified. There is experimental evidence that an exaggerated
inflammatory response might also promote tissue injury,
contributing to chronic cardiac dilatation [10, 11].
Elevated plasma CRP concentration is associated with
an unfavourable outcome in acute MI and allows clinicians
to stratify patients in terms of their risk of death and heart
failure [12, 13]. Additionally, evaluation of CRP concentra-
tion in patients with acute coronary syndromes provides
prognostic information independent from the classical risk
factors and enhances the value of well-established risk scores
[13]. However, there is limited and partially conflicting data
regarding the possible link between CRP and the develop-
ment of LVR in humans [14–16]. Moreover, quantification
of the potential additive effect of plasma CRP concentration
besides well-established LVR predictors warrants further
investigations.
We therefore set out to assess the value of in-hospital
measurement of plasma CRP concentration in predicting the
long-term risk of LVR in patients with a first STEMI, treated
with primary percutaneous coronary intervention (pPCI).
2. Material and Methods
2.1. Study Design and Patient Characteristics. This study
was designed as a single-center prospective observational
cohort trial in the setting of first STEMI treated with pPCI,
with 221 consecutive patients enrolled in the Department
of Cardiology and Internal Medicine of Antoni Jurasz Uni-
versity Hospital in Bydgoszcz between 25th November 2005
and 27th November 2008. The inclusion criteria were as
follows: (i) typical stenocardial chest pain of at least 30
minutes’ duration, (ii) onset of symptoms <12 h before
hospital admission, and (iii) electrocardiographic features of
acute STEMI (ST-segment elevation ≥0,1 mV or ≥0,2 mV in
at least 2 continuous limb or precordial leads, respectively).
The exclusion criteria included (i) prior coronary revascu-
larization, (ii) cardiogenic shock on admission, (iii) heart
failure (New York Heart Association class III or IV), (iv)
bundle branch block, (v) permanent atrial fibrillation, (vi)
haemodynamically significant valvular heart disease, (vii)
primary cardiomyopathy, (viii) severe arterial hypertension,
(ix) creatinine concentration >176.8 mmol/L, (x) the pres-
ence of features suggestive of an active inflammatory process
on admission, and (xi) therapy with steroids, immunosup-
pressive agents, and nonsteroidal anti-inflammatory drugs
(excluding low doses of aspirin).
The study endpoint was LVR which was defined accord-
ing to the previously validated criterion [2, 4], as a relative
>20% increase in end-diastolic left ventricular volume
(LVEDV) by echocardiography seen at 6-month followup
compared with the baseline at discharge. The patients were
divided, according to the presence of LVR at 6 months after
STEMI into subgroups with (LVR group) and without (no
LVR group) LVR.
Approval from the local Bioethics Committee at Col-
legium Medicum in Bydgoszcz was obtained. All patients
gave their written, voluntary, informed consent for partici-
pation in the study.
2.2. Pharmacotherapy. At the first contact with health care
providers immediately after establishing the diagnosis of
STEMI all patients were pretreated with an intravenous bolus
of unfractionated heparin (70 IU/kg, up to 5000 IU) and oral
loading doses of clopidogrel (600 mg) and aspirin (300 mg).
At the catheterization laboratory, second dose of unfrac-
tionated heparin was administered intraarterially in a
weight-adjusted manner (up to 100 IU/kg) or under acti-
vated clotting time guidance (to the target range of 200–
250 seconds) when abciximab was intended. Abciximab was
given at the discretion of the invasive cardiologist. Through-
out the study period clopidogrel and aspirin 75 mg q.d.
were continued in all patients. Concomitant medications
in the majority of patients included perindopril and long-
acting metoprolol in doses adjusted for resting heart rate
and blood pressure, and simvastatin 40 mg q.d. (Table 1).
Additionally, at hospital discharge 12 (6.1%) patients were
treated with spironolactone while 11 (5.6%) participants
received nonpotassium-sparing diuretics.
2.3. Coronarography and pPCI. Coronarography and pPCI
were performed using a standard femoral approach. The use
of aspiration thrombectomy during the intervention was left
to the operator’s discretion. Intracoronary stents were rout-
inely implanted. Coronary artery stenosis was measured with
quantitative coronary angiography. Epicardial coronary flow
was assessed according to the TIMI (Thrombolysis in Myo-
cardial Infarction) score and TFC (TIMI frame count), and
myocardial perfusion according to the TMPG (TIMI Myo-
cardial Perfusion Grade).
2.4. Echocardiography. Transthoracic echocardiographic re-
cordings employing the Doppler technique were acquired at
hospital discharge and 6 months after STEMI using a Philips
SONOS 7500 Ultrasound System, in accordance to the pro-
tocol recommended by The American Society of Echocar-
diography [17]. Echocardiographic recordings were assessed
offline by two independent experienced echocardiographers
blinded to the values of biomarker measurement. Mea-
surements are reported as an average of three consecutive
cardiac cycles. The corresponding echocardiographic results
obtained by each echocardiographer were averaged. The
inter- and intraobserver coefficients of variation for left
ventricular end-diastolic volume (LVEDV) assessed in first
50 patients were below 5.0% and below 2.5%, respectively.
Left ventricular (LV) volumes and left ventricular ejec-
tion fraction (LVEF), a marker of global LV systolic function,
were calculated using the modified Simpson rule [17]. Wall
motion score index (WMSI), reflecting regional LV systolic
function, was derived as a sum of all scores divided by
the number of segments visualized, implementing the 16-
segment model of LV segmentation and assigning a score
from 1 point (normal) to 4 points (dyskinesia), respectively
[18]. Left ventricular mass (LVM) was calculated according
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P for comparison between
groups with and without LVR
Age (years) 56.0 (50.0–64.0) 54.0 (49.0–63.0) 57.0 (51.0–64.0) NS
Gender (male/female) n (%) 153/45 (77.3/22.7) 46/9 (83.6/16.4) 107/36 (74.8/25.2) NS
Anterior location of STEMI n (%) 89 (43.6) 30 (54.6) 58 (40.6) NS






Risk factors for coronary artery disease
Body mass index (kg/m2) 26.8 (24.2–29.1) 27.5 (24.8–30.4) 26.2 (24.1–28.8) NS
Hypertension n (%) 82 (41.4) 27 (49.1) 55 (38.5) NS
Diabetes mellitus n (%) 40 (20.2) 13 (23.6) 27 (18.9) NS
Current or ex-smoker n (%) 131 (66.2) 34 (61.8) 97 (67.8) NS
Medical treatment at hospital discharge
Long-acting metoprolol n (%) 196 (99.0) 55 (100.0) 141 (98.6) NS
Perindopril n (%) 194 (98.0) 53 (96.4) 141 (98.6) NS
Simvastatin n (%) 197 (99.5) 55 (100.0) 142 (99.3) NS
Spironolactone n (%) 12 (6.1) 5 (9.1) 7 (4.9) NS
Nonpotassium-sparing diuretics
n (%)
11 (5.6) 4 (7.3) 7 (4.9) NS
LVR: left ventricular remodelling; STEMI: ST-segment elevation myocardial infarction.
to the Devereux formula [19]. Measurements of peak mitral
annular velocities were obtained for four basal segments of
LV (septal, lateral, inferior, and anterior) using pulsed tissue
Doppler echocardiography with the Doppler gate targeted at
the junction of LV walls with the mitral annulus in 4- and 2-
chamber views. Average peak systolic mitral annular velocity
(S′), a marker of longitudinal LV systolic function, was
obtained. Diastolic LV function was assessed using pulsed
Doppler echocardiography and pulsed tissue Doppler echo-
cardiography by measurements of peak velocity transmitral
flow in the early phase (E) and during atrial systole (A) to
obtain the E/A ratio, deceleration time of early transmitral
flow and the E/E′ ratio, where E′ is the average peak early
diastolic mitral annular velocity.
2.5. Blood Sampling and Laboratory Analyses. Peripheral ven-
ous blood samples were collected using ethylenediaminete-
traacetic acid tubes. When centrifuged, the plasma was stored
at −80◦C until analyzed.
CRP plasma concentrations were measured with an
ultrasensitive latex immunoassay (CRP Vario test, analyzer:
ARCHITECT ci 8200, ABBOTT) on admission, 24 h after
admission and at discharge. B-type natriuretic peptide
(BNP) plasma concentration was evaluated with a chemi-
luminescent microparticle immunoassay (analyzer: ARCHI-
TECT ci 8200, ABBOTT) on admission and at discharge.
The limits of detection for CRP and BNP were 0.1 mg/L and
10 pg/L, respectively. The intraassay coefficients of variation
were below 2.0% for CRP and below 5.0% for BNP, while the
inter-assay coefficients of variation were below 1.0% for CRP
and below 5.0% for BNP, respectively.
Additional biochemical measurements were performed
using the following methods: blood glucose—hexokinase
enzymatic glucose assay (Abbott, Wiesbaden, Germany);
creatine kinase MB isoenzyme—CK-MB liquid immuno-
logical test assay (Sentinel Diagnostics, Milan, Italy);
troponin I—chemiluminescence immunoassay STAT Tro-
ponin-I Architect System (Abbott, Middletown, OH, USA);
creatinine—spectrophotometric creatinine assay (Abbott,
Wiesbaden, Germany); total cholesterol, high-density-lipo-
protein cholesterol and triglycerides—enzymatic choles-
terol, ultrahigh-density-lipoprotein, and triglyceride assays
(Abbott, Wiesbaden, Germany), respectively. Low-density-
lipoprotein cholesterol concentration was calculated accord-
ing to the Friedewald formula.
2.6. Statistical Analysis. Due to major advances in STEMI
management resulting in improved survival and lower
prevalence of postinfarct LVR along with reductions in mean
CRP values in STEMI patients in recent years, we decided to
perform an internal pilot study of first 50 patients for esti-
mating the final sample size. LVR was present in 10 (25.0%)
subjects. Means and standard deviations of CRP concentra-
tions in the first 50 patients assessed for the overall popula-
tion and for patients with and without LVR were (1) on
admission 2.6 ± 2.2, 2.7 ± 2.8, and 2.6 ± 2.1 mg/L (2) at
24 h after admission 11.5 ± 10.9, 19.4 ± 19.4, and 9.5 ±
6.5 mg/L (3) at discharge 13.0 ± 13.0, 12.3 ± 12.3, and
13.2 ± 13.4 mg/L. Based on these results and assuming a
2-sided alpha value of 0.05, we calculated using the t-test
for independent variables that enrolment of 195 patients
would provide a 99.8% power to demonstrate a significant
difference in CRP concentrations at 24 h between patients
with and without LVR. We decided to obtain such high
power to be able to perform credible multivariate analyses.
To compensate for potential withdrawal of consent or loss
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of study participants due to other reasons, we enrolled 26
additional patients.
The Shapiro-Wilk test demonstrated lack of normal dist-
ribution for the majority of the investigated variables.
Therefore continuous variables were presented as medians
and their interquartile ranges. Depending on the presence
or absence of normal distribution, intergroup comparisons
were performed with the Student’s t-test for independent
samples or the Mann-Whitney unpaired rank sum test,
whereas the Student’s t-test for paired samples or the
Wilcoxon matched-paired rank sum test were applied for
comparisons within the groups. Categorical variables were
compared using the χ2 test with the Yates’ correction if
required.
Univariate and multivariate logistic regression models
were used to identify predictors of LVR. Variables with a P
value of <0.1 in the univariate analysis and inflammatory
markers independently of their P values were introduced
into the multivariate logistic regression model. Subsequently,
variables without any significant impact on the LVR preva-
lence (P ≥ 0.05) were one after another removed from the
multivariate model according to their decreasing P values.
Lastly, to optimize our final multivariate model, we investi-
gated whether addition of variables linked with LVR in
previous studies [2, 6, 7, 14] but not in our univariate
analysis (time from onset of pain to balloon inflation,
LVEF at baseline, wall motion score index at baseline, left
ventricular end-systolic volume at baseline, TIMI 3 flow in
infract-related artery after pPCI, and presence of multivessel
coronary artery disease) would improve its predictive value.
Relations between the investigated variables and the likeli-
hood of LVR were estimated with the use of odds ratios (OR)
and their 95% confidence intervals (95% CI). The optimal
cutoff points were determined using the receiver operator
characteristic (ROC) analysis.
The impact of numerous variables upon a quantitative
variable was assessed using the multiple regression model.
A two-sided difference was considered significant at P <
0.05. The statistical analysis and sample size calculation
were carried out using the Statistica 10.0 package (StatSoft,
Tulsa, OK, USA), while MedCalc 12.0 (MedCalc Software,
Mariakerke, Belgium) statistical software was applied for the
ROC analysis.
3. Results
3.1. Patients. Of the total number of 221 patients enrolled in
the study initially, twelve patients were excluded during hos-
pitalization due to false diagnosis of STEMI (3 patients),
echocardiographic images insufficient for quantitative anal-
ysis (4 patients), expected difficulties in cooperation due to
alcohol abuse and dementia (2 patients), dopamine therapy,
acute pharyngitis, and abdominal aneurysm rupture (1
patient each). Eleven patients were excluded from further
analysis due to incomplete data, including 3 participants
who died, 2 with the diagnosis of neoplasmatic disease dur-
ing followup, and 6 who did not attend the 6-month fol-
lowup visit. The final study group consisted of 198 patients
including 45 (22.7%) women and 153 (77.3%) men (Table 1).
The major adverse cardiac events observed during 6
months of followup in patients with and without LVR
included 5 re-MI (2 (3.6%) versus 3 (2.1%); P = NS), 24
episodes of unstable angina (7 (12.7%) versus 17 (11.5%)
P = NS), and 13 episodes of the development of sympto-
matic heart failure (4 (7.3%) versus 9 (6.3%); P = NS).
Additionally, within 6 months after the study enrollment 28
patients underwent percutaneous coronary intervention (9
(16.4%) versus 19 (13.3%); P = NS) including 8 patients
scheduled for an elective procedure during the index hospi-
talization (2 (3.6%) versus 6 (4.2%); P = NS). Furthermore,
at 6-month followup, 4 patients had been treated with
elective coronary bypass grafting scheduled during the index
hospitalization (1 (1.8%) versus 3 (2.1%); P = NS).
3.2. Clinical, Angiographic, and Echocardiographic Assessment.
LVR at 6 months after STEMI was present in 55 (27.8%)
patients (Table 1).
In patients with LVR at 6 months after discharge,
when compared to those without LV dilatation, anterior
location of STEMI, and culprit lesion in the left descending
artery were numerically more frequent (Table 1). Similarly,
these patients had a higher prevalence of hypertension
and diabetes but again the differences were not statistically
significant, even though cardiovascular pharmacotherapy at
hospital discharge was comparable in both groups (Table 1).
We found no differences among the groups in the frequency
of angina proceeding STEMI and the diagnosis of heart
failure (New York Heart Association class I or II) prior to
admission (data not presented).
The LVR group presented with insignificantly longer
time from the onset of pain to balloon inflation and noti-
ceably less favourable pre-pPCI angiographic indices of flow
in the infarct-related artery (Table 2). However, similar final
angiographic results of pPCI were achieved regardless of the
future LVR development.
At baseline there were no significant differences in echo-
cardiographic indices between patients with and without
LVR at 6 months except for the values of markers of LV dias-
tolic function (Table 3).
At 6-month followup the LVR group had significantly
larger diameters of left atrium and left ventricle, higher systo-
lic and diastolic LV volumes, and greater LVM than patients
without LV dilatation (Table 3). Similarly, in patients with
LVR, we observed significantly higher values of WMSI and
markedly lower values of LVEF and average peak systolic
mitral annular velocity, indicating more severe impairment
of regional, global, and longitudinal LV systolic function
(Table 3). Also the echocardiographic indices of LV diastolic
function were more abnormal in the LVR group (Table 3).
3.3. Biomarkers. Patients who developed LVR, compared to
those without LV dilatation, presented with a significantly
higher maximal activity of izoenzyme MB of creatine kinase
and noticeably increased white blood cell count on admission
and at 24 h after admission (Table 2).
Plasma CRP concentration steeply rose during the first
24 h of hospitalization (P < 0.001), mainly in the LVR group,
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Table 2: Angiographic and biochemical characteristics of the study population.










IRA: LAD/non-LAD n (%) 92 (46.5)/106 (53.5) 32 (58.2)/23 (41.8) 60 (42.0)/83 (58.0) NS
Multivessel coronary artery disease n (%) 119 (60.0%) 38 (69.1%) 81 (56.6%) NS
TIMI 3 flow in IRA n (%)
Before pPCI 55 (27.8) 10 (18.2) 45 (31.5) <0.05
After pPCI 185 (93.4) 49 (89.1) 136 (95.1) NS
TMPG 3 after pPCI n (%) 94 (46.1) 30 (54.6) 62 (43.4) NS
Patients with implanted stents n (%) 196 (99.0) 54 (98.2) 142 (99.3) NS
Abciximab use n (%) 49 (24.7) 17 (30.9) 32 (22.4) NS
Biochemical parameters
Creatinine (μmol/L) 82.7 (72.0–95.9) 82.7 (79.6–89.3) 82.2 (70.7–97.2) NS
Admission glucose (mmol/L) 7.6 (6.8–9.3) 7.8 (6.8–9.6) 7.4 (6.7–9.2) NS
TnImax (ng/mL) 46.3 (11.7–50.0) 50.0 (15.3–50.0) 36.7 (10.5–50.0) NS
CK-MBmax (U/L) 102.5 (58.0–160.0) 134.0 (87.0–206.0) 95.0 (54.0–141.0) <0.01
LDL cholesterol (mmol/L) 3.76 (3.23–4.45) 3.75 (3.39–4.40) 3.78 (3.21–4.45) NS
HDL cholesterol (mmol/L) 1.32 (1.16–1.50) 1.32 (1.19–1.50) 1.34 (1.14–1.50) NS
Triglycerides (mmol/L) 1.01 (0.67–1.59) 0.98 (0.64–1.51) 1.02 (0.69–1.59) NS
Leukocyte count on admission (103/μL) 11.3 (9.1–13.3) 12.0 (10.5–13.7) 10.6 (8.7–12.8) <0.05
Leukocyte count 24 h after admission (103/μL) 10.1 (8.6–11.7) 10.3 (9.2–12.3) 10.1 (8.2–11.3) <0.05
BNP on admission (pg/mL) 51.9 (25.9–102.5) 50.5 (25.3–121.0) 52.8 (26.8–93.0) NS
BNP at discharge (pg/mL) 124.8 (70.5–233.0) 159.6 (74.6–358.2) 114.0 (61.5–192.7) <0.05
BNP: B-type natriuretic peptide; CK-MBmax: maximal activity of izoenzyme MB of creatine kinase; HDL cholesterol: high-density-lipoprotein cholesterol;
IRA: infarct-related artery; LAD: left anterior descending artery; LDL cholesterol: low-density-lipoprotein cholesterol; LVR: left ventricular remodelling; pPCI:
primary percutaneous coronary intervention; TnImax: maximal concentration of troponin I; TIMI: Thrombolysis in Myocardial Infarction score; TMPG: TIMI
myocardial perfusion grade.
and persisted elevated at discharge (Figure 1). CRP concen-
tration 24 h after admission was higher in the LVR group as
compared to the patients without LV dilatation at 6 months
(15.8 (5.9–31.3) versus 9.5 (5.8–15.6) mg/L; P < 0.05).
Additionally, as presented in Figure 2, we found a signi-
ficant heterogeneity of the prevalence of LVR at 6 months
among patients classified in quartiles according to CRP
concentrations 24 h after admission. The prevalence of LVR
at 6 months after STEMI was considerably higher for patients
from the highest quartile of CRP concentrations 24 h after
admission as compared to those from any other quartile.
BNP concentration increased during hospitalization in
all patients (P < 0.001). However, its remarkably higher
values were observed in the LVR group, mainly at discharge
(Table 2).
3.4. Predictors of LVR. Predictors of LVR at 6 months
after discharge revealed by univariate logistic regression
analysis among all demographic, clinical, angiographic, and
biochemical variables listed in Tables 1 and 2 as well as
among the echocardiographic variables at discharge shown
in Table 3 are presented in Table 4. The final model of multi-
variate logistic regression analysis, including also base-
line echocardiographic variables, found high plasma CRP
concentration 24 h after admission, elevated BNP plasma
concentration at discharge, increased body mass index, and
low LVEDV at discharge to be independent predictors of LVR
at 6 months after STEMI (Table 4).
When adjusted for plasma CRP concentration, anterior
location of STEMI, maximal concentration of troponin I,
LVEF at discharge, leukocyte count, and post-PCI flow in
infarct-related artery below TIMI 3 grade were no longer
associated with the presence of LVR at 6 months in the
multivariate analysis.
3.5. Optimal Cutoff Values for the Prediction of LVR. A ROC
analysis to assess the diagnostic accuracy for the prediction
of LVR at 6 months after STEMI revealed areas under the
curves of 0.61 (95% confidence interval 0.54–0.68; P <
0.05), 0.61 (95% confidence interval 0.54–0.68; P < 0.05),
0.59 (95% confidence interval 0.50–0.68; P = NS) and
0.53 (95% confidence interval 0.46–0.60; P = NS) for
plasma CRP concentration 24 h after admission, plasma
BNP concentration at discharge, and body mass index and
LVEDV at discharge, respectively. The corresponding opti-
mal cutoff values were 14.2 mg/L for CRP 24 h after admis-
sion (sensitivity 54.5%, specificity 72.7%, positive predictive
value 43.5%, and negative predictive value 80.6%) and
237.3 pg/L for plasma BNP concentration at discharge
(sensitivity 40.0%, specificity 82.5%, positive predictive value
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Table 3: Echocardiographic characteristics of the study population. Echocardiographic indices are derived from 2D, Doppler echocardio-
graphy, and tissue Doppler echocardiography at hospital discharge and at 6 month after discharge, respectively.






P for comparison between groups
with and without LVR
Echocardiographic indices at discharge
LA (mm) 39.0 (36.0–42.0) 39.0 (36.0–45.0) 39.0 (36.0–41.0) NS
LVEDd (mm) 49.0 (45.0–53.0) 49.0 (43.0–53.0) 49.0 (45.0–53.0) NS
LVESd (mm) 34.0 (30.0–37.0) 34.0 (30.0–38.0) 33.0 (30.0–36.0) NS
LVMI (g/m2) 114.3 (96.7–132.3) 114.4 (99.0–133.4) 114.1 (96.5–132.3) NS
LVEDV (mL) 97.0 (82.0–118.0) 95.0 (81.0–118.0) 99.0 (83.0–118.0) NS
LVEDVI (mL/m2) 50.5 (44.0–60.8) 48.7 (42.0–57.9) 51.4 (45.6–62.1) NS
LVESV (mL) 53.5 (44.0–68.0) 57.0 (43.0–66.0) 52.0 (44.0–68.0) NS
LVESVI (mL/m2) 27.7 (23.1–35.0) 26.9 (23.0–34.1) 27.7 (23.2–35.7) NS
LVEF (%) 44.8 (40.0–49.4) 43.0 (38.5–48.0) 45.0 (40.4–49.9) NS
WMSI (pts) 1.5 (1.38–1.75) 1.63 (1.38–1.75) 1.5 (1.38–1.75) NS
S′ (cm/s) 7.01 (6.14–8.15) 6.75 (5.98–7.9) 7.15 (6.3–8.15) NS
E/A 0.84 (0.66–1.09) 0.85 (0.68–1.12) 0.82 (0.64–1.06) <0.05




E/E′ 9.6 (7.3–11.8) 9.9 (5.3–20.6) 9.5 (7.3–11.5) NS
Echocardiographic indices at 6 month after discharge
LA (mm) 40.0 (37.0–44.0) 42.0 (38.0–46.0) 40.0 (37.0–43.0) <0.05
LVEDd (mm) 50.0 (46.0–54.0) 53.0 (47.0–56.0) 49.0 (46.0–53.0) <0.01
LVESd (mm) 34.0 (31.0–37.0) 36.0 (32.0–40.0) 33.0 (31.0–36.0) <0.01








LVEDVI (mL/m2) 57.2 (48.8–68.3) 66.6 (55.2–86.0) 54.0 (46.5–65.3) <0.001
LVESV (mL) 57.0 (46.0–74.0) 72.0 (55.5–94.0) 51.2 (43.0–68.0) <0.001
LVESVI (mL/m2) 29.2 (24.8–38.9) 35.3 (27.8–46.1) 27.7 (23.5–35.9) <0.001
LVEF (%) 46.0 (42.3–52.0) 44.0 (38.0–49.0) 46.6 (43.0–52.0) <0.01
WMSI (pts) 1.44 (1.31–1.63) 1.5 (1.38–1.75) 1.44 (1.31–1.63) <0.01
S′ (cm/s) 6.98 (6.13–8.13) 6.5 (5.55–7.58) 7.08 (6.23–8.28) <0.01
E/A 0.85 (0.67–1.12) 0.89 (0.75–1.37) 0.82 (0.64–1.06) <0.01




E/E′ 8.9 (7.5–11.1) 9.7 (5.7–22.4) 8.7 (7.2–10.1) <0.05
DT: Deceleration time of early transmitral flow; E: peak velocity of early transmitral flow; A: peak velocity of transmitral flow during atrial systole; E′:
average peak early diastolic mitral annular velocity; LA: left atrium; LVEDd: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic
volume; LVEDVI: left ventricular end-diastolic volume index; LVEF: left ventricular ejection fraction; LVESd: left ventricular end-systolic diameter; LVESV:
left ventricular end-systolic volume; LVESVI: left ventricular end-systolic volume index; LVMI: left ventricle mass index; LVR: left ventricular remodelling; S′:
average peak systolic mitral annular velocity; WMSI: wall motion score index.
46.8%, and negative predictive value 78.1%), respectively.
Comparison of the ROC curves demonstrated comparable
diagnostic accuracies for both biomarkers (P = NS).
3.6. Determinants of an Increase in LVEDV. To further
investigate the relationship between plasma CRP concen-
tration and the development of LVR, we applied multiple
regression analysis to determine which of the demographic,
clinical, angiographic, and biochemical parameters listed in
Tables 1, 2 and 3 affect an increase in LVEDV between
hospital discharge and 6-month followup. High plasma CRP
concentration 24 h after admission, elevated BNP values at
discharge, and low LVEDV at discharge, but not high body
mass index were independently associated with an increase
in LVEDV (Table 5).
4. Discussion
This study shows the relationship between the inflammatory
reaction during STEMI and the development of LVR in
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Figure 1: Plasma C-reactive protein concentration on admission,
24 h after admission and at hospital discharge in patients after acute
ST-segment elevation myocardial infarction with and without left
ventricular remodelling at 6 months after hospital discharge. Results
are presented as medians, interquartile ranges, and ranges.
P for heterogeneity < 0.01
= 3.48; 95% CI 1.76–6.88OR for 4th quartile versus any other quartile













CRP ≤ 5.8 5.8 > CRP < 10.3 10.3 ≥ CRP < 19.7 CRP ≥ 19.7
(mg/L)
Figure 2: Prevalence of left ventricular remodelling at 6 months
after hospital discharge after acute ST-segment elevation myocardial
infarction in patients classified according to the increasing quartiles
of C-reactive protein concentration 24 h after admission. CRP— C-
reactive protein.
long-term followup in patients undergoing pPCI. Moreover,
the intensity of early inflammatory response, assessed by
plasma CRP concentration measured 24 h after admission to
hospital, was found to be an independent predictor of LVR at
6 months after a first STEMI. Furthermore, the robustness of
our findings was confirmed in a multiple regression analysis
which indicated the presence of an independent association
between incremental plasma CRP concentrations and an
increase in LVEDV, a marker of LVR. On the other hand, the
ROC analysis revealed a limited discriminative value of CRP
assessment in terms of the postinfarct LVR prediction.
To our best knowledge, it is the first adequately powered
study linking in-hospital plasma CRP concentration and
postinfarct LVR at 6 months after discharge, conducted
exclusively in a STEMI population undergoing pPCI. In a
small study (n = 48) by Mather et al., CRP level measured
2 days after reperfusion was found to be a predictor of LVR
at 3 months [20]. Similarly, Ørn et al. found in 42 patients
undergoing pPCI a significant correlation between plasma
CRP concentration assessed 2 days after the intervention
and the parameters of LVR at 2 months after STEMI [15].
In accordance with these studies Fertin et al. demonstrated
a relationship between in-hospital CRP level and LVR in
long-term followup in 226 patients with a first anterior
Q-wave MI, but in apparent contrast to our study, CRP
concentration was not independently associated with LVR
[14]. This discrepancy among the trials may be related
to differences in the sample sizes, heterogeneity of study
populations, modalities of treatment and timing of blood
sampling. The greater prevalence of LVR in the study by
Fertin et al. (38%) as compared to previous and our studies
(28–30%) may be caused by exclusive inclusion of patients
with anterior MI, only 52% of whom underwent pPCI [14].
It should be acknowledged that a single blood sampling
for plasma CRP concentration measure drawn only at hos-
pital discharge (i.e., when the intensity of the inflamma-
tory reaction is already decreasing) may also provide dif-
ferent results [14]. Multiple blood sampling throughout the
hospital period to obtain CRP peak values employed in our
study revealed lack of difference in plasma CRP concen-
tration at discharge between the LVR and non-LVR groups.
Thus, determination of CRP level at this time point is
unlikely to improve the accuracy of LVR prediction. It
should be emphasized that our population of patients was
homogenous, with strictly applied criteria of inclusion and
exclusion. In our opinion, this, together with the delivery
of unison invasive and pharmacologic treatment, allowed us
to minimise the risk for confounding factors and enabled to
reliably quantify the relationship between plasma CRP con-
centration and the development of postinfarct LVR.
Our study confirms previous evidence of the presence of
a significant increase in CRP concentration in the course of
MI [8, 10, 15]. As reported by several studies, elevated CRP
levels after MI are associated with adverse clinical outcome,
including cardiac rupture, heart failure, and cardiac death
[9, 12, 13]. Myocardial necrosis due to abrupt closure of
coronary artery, in case of acute MI, leads to a systemic
and regional humoral and cellular inflammatory response
aiming to promote the local myocardial healing process and
scar formation [21, 22]. In the early phase of MI, cytokines
play an important cytoprotective role, mainly by reduc-
ing cell apoptosis [10]. However, in case of exuberant inflam-
matory reaction, high tissue cytokine levels may persist for
a long time and the extent of the primary ischaemically
damaged myocardial tissue may paradoxically increase [21].
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Table 4: Predictors of postinfarct left ventricular remodelling in univariate and multivariate analyses. Univariate analysis shows demo-
graphic, clinical, angiographic, biochemical, and discharge echocardiographic parameters from Tables 1–3 with a P value <0.1 as well as
BNP, CRP, and leukocyte count independently of their P values, while results of multivariate analysis are restricted to variables with a P value
<0.05. Results are presented according to decreasing values of odds ratios.
Univariate analysis
OR 95% CI P
CRP on admission (for a 10 mg/L increase) 2.99 0.60–14.92 NS
IRA: LAD versus non-LAD 1.92 1.02–3.63 <0.05
Anterior versus nonanterior wall STEMI 1.76 0.94–3.30 0.077
Diabetes mellitus 1.46 0.95–2.24 0.086
CRP 24 h after admission (for a 10 mg/L increase) 1.29 1.08–1.56 <0.01
TnImax (for a 10 ng/mL increase) 1.18 0.99–1.40 0.051
BNP at discharge (for a 100 pg/mL increase) 1.14 1.02–1.28 <0.05
Body mass index (for a 1 kg/m2 increase) 1.10 1.01–1.20 <0.05
Leukocyte count on admission (for a 103/μL increase) 1.10 0.99–1.22 0.068
Leukocyte count 24 h after admission (for a 103/μL increase) 1.09 0.97–1.23 NS
BNP on admission (for a 100 pg/mL increase) 1.08 0.88–1.33 NS
CK-MBmax (for a 10 U/L increase) 1.07 1.03–1.11 <0.001
CRP at discharge (for a 10 mg/L increase) 1.05 0.86–1.30 NS
Multivariate analysis
CRP 24 h after admission (for a 10 mg/L increase) 1.29 1.04–1.60 <0.05
BNP at discharge (for a 100 pg/mL increase) 1.21 1.05–1.39 <0.01
Body mass index (for a 1 kg/m2 increase) 1.10 1.01–1.21 <0.05
LVEDV at discharge (for a 1 mL increase) 0.98 0.96–0.99 <0.01
BNP: B-type natriuretic peptide; CI: confidence interval; CK-MBmax: maximal activity of izoenzyme MB of creatine kinase; CRP: C-reactive protein; IRA:
infarct-related artery; LAD: left anterior descending artery; LVEDV: left ventricular end-diastolic volume; MI: myocardial infarction; NYHA: New York Heart
Association; OR: odds ratio; STEMI: ST-segment elevation myocardial infarction; TnImax: maximal concentration of troponin I.
Table 5: Impact of demographic, clinical, angiographic, and biochemical variables from Tables 1, 2, and 3 on an increase in end-diastolic
left ventricular volume between hospital discharge and 6-month followup.









Intercept 28.94 4.75 <0.0001
CRP 24 h after admission (for a 10 mg/L increase) 0.21 0.07 2.08 0.72 <0.005
LVEDV at discharge (for a 1 mL increase) −0.32 0.07 −0.22 0.05 <0.0001
BNP at discharge (for a 100 pg/mL increase) 0.25 0.07 1.64 0.48 <0.0008
BNP: B-type natriuretic peptide; CRP: C-reactive protein; LVEDV: end-diastolic left ventricular volume.
Plasma CRP concentration increases following the cytokines
activation in the first hours of MI [8, 15]. The rapid and sus-
tained rise in plasma CRP concentration, in the early phase
of hospitalization in patients with LVR seen in our study,
reflects the severity of the inflammatory reaction within the
infarcted area in patients with STEMI. CRP binds to phos-
phocholine groups of necrotic myocardial cell membranes,
facilitating complement activation, and thus promoting
further inflammatory response, injury of myocardial cells,
and expansion of necrosis [23–26]. An experimental study
by Takahashi et al. has clearly demonstrated that increased
CRP expression exacerbates LV dysfunction and promotes
LVR after MI [11]. Literature data also suggests that not only
is CRP an inflammatory marker, but it should also be con-
sidered as an inflammatory mediator holding prothrombotic
and proapoptotic properties [23–26]. There is evidence that
apoptosis, both at the site of infarction and in unaffected
regions of LV, correlates with unfavourable postinfarct LVR
and the occurrence of heart failure after MI [27]. The size of
the healed infarction has been demonstrated to be a major
determinant of long-term LVR and a stronger predictor of
all-cause mortality than LVEF [28]. The deleterious effect of
CRP on postinfarct LVR may be independent of myocardial
necrosis size and may be associated with increased apoptotic
rates, macrophage infiltration, monocyte chemotactic pro-
tein expression-1, and matrix metalloproteinase-9 activity in
the border zone [11].
It is currently known that a strong correlation exists
between CRP levels, infarct size, and biochemical markers of
myocardial necrosis [15, 29, 30]. The findings by Ørn provide
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a potential pathophysiological explanation for the associ-
ation between CRP levels and LVR, by linking peak CRP
levels with infarct size after 2 months [15]. Also in our study
including patients with a first STEMI undergoing pPCI, the
LVR group exhibiting a more pronounced inflammatory
response, presented with larger infarctions as assessed by
enzymatic assays, mainly of anterior location. The sustained
increase in plasma CRP concentration in the course of MI
observed in the group of patients with LV dilatation may
have been associated with a greater extent of myocardial
damage reflected by the values of cardiac necrosis markers.
In contrast, Haase et al. did not confirm this observation
possibly due to different clinical characteristics of the study
population admitted for rescue coronary angioplasty, 30% of
whom had a previous MI that might have precluded accurate
assessment of new myocardial damage [31].
We also found one of the markers of STEMI-induced
LV haemodynamic impairment in the course of STEMI (i.e.,
BNP plasma level at discharge) to be an important inde-
pendent predictor of cardiac dilatation after discharge. When
compared with the no LVR group, patients with LVR present
at 6-month followup, not only showed higher initial BNP
levels, but also their persistence during hospitalization. Eva-
luation of BNP has been known as a useful tool for detect-
ing LV dysfunction and as a risk marker for adverse clini-
cal outcome in patients with STEMI [32]. Cardiac natri-
uretic peptides reflect the ventricular function impairment
and haemodynamic decompensation in the course of MI.
According to our results, they could also be useful for
predicting LVR following STEMI since they take into account
not only the loss of necrotic myocardium, infarct expan-
sion, and increased LV wall stress but also the effects of
compensatory reaction developing during early stages of LV
remodelling for example, increased contractility of the intact
muscle [33, 34]. The inclusion of both biomarkers (CRP and
BNP) into our analysis might have improved risk prediction
as these biomarkers provide additive prognostic information
in patients with acute coronary syndromes [35]. However, as
reported by Fertin in a study including patients with a first
anterior STEMI, despite existing correlations between CRP
and BNP and long-term LVR, none of these biomarkers at
discharge was independently predictive of LVR at 12 months
[14].
Noteworthy, we also demonstrated a link between low
LVEDV at discharge and the development of LVR in long-
term followup. This somewhat unexpected observation is in
line with previous findings [2, 36]. Interpreting these results
Bolognese et al. hypothesize that LVR predominantly occurs
in patients with large functional infarct size that initially
does not compromise the overall LV cavity dimensions and
function [2].
Furthermore, in our study overweight and obese patients
were more likely to present with LVR at 6 months. High
body mass index is linked with both proinflammatory state
and a rise in total blood volume resulting in increased card-
iac output [37]. Obesity subsequently leads to LV dilation,
increased LV wall stress, eccentric LV hypertrophy, and LV
diastolic dysfunction [37]. Our results correspond with pre-
vious observations from a mice model of MI that indicated
in diet-induced obese animals, when compared to controls,
a significant reduction in collagen deposition within the
scar along with a more pronounced LV dilation and cardiac
hypertrophy, indicative of adverse LVR [38].
5. Limitations of the Study
Although our study throws some new light on the mech-
anisms of LVR development in patients treated with pPCI
for their first STEMI, it has several limitations. First, it
lacks adequate power to assess clinical end points. The low
rate of clinical events observed in our patients is driven
by high efficacy of modern MI management, medium-term
followup and application of strict inclusion and exclusion
criteria. Second, due to early achievement of reperfusion the
patients had relatively well-preserved LV function. Third, we
did not account in our calculations for diurnal and seasonal
variations in CRP concentration. Fourth, further efforts
are warranted to confirm the clinical significance of our
findings and to fully explain the mechanisms through which
augmentation of the inflammatory process contributes to the
occurrence of LVR. Fifth, we did not assess subpopulations of
leukocytes but only their overall count which precludes any
investigation of the potential relationship between leukocyte
types, CRP concentration, and the development of LVR.
Sixth, the enrolment of participants to our study was
completed four years ago but this fact seems to have no major
impact on the value of obtained results as STEMI manage-
ment has not been markedly changed since then. Finally, as
the LVR and non-LVR groups differed in several aspects, it
cannot be fully excluded that the higher incidence of LVR
and the modest difference in CRP elevations may be related
to the fact that the LVR-group altogether had a more frequent
anterior location of STEMI as well as a higher body mass
index and prevalence of both hypertension and diabetes.
However, differences for each of these potential confounders
assessed separately were statistically insignificant between the
LVR and non-LVR groups.
6. Conclusions
The measurement of CRP plasma concentration at 24 h after
admission possesses a statistically significant but modest
value in the prediction of long-term LVR in patients after a
first STEMI treated by pPCI.
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